Clinical Trial

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Study acronym: SHIFT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
Protocol Amendment History 4 changes
notable Trial sites expanded: 26 -> 29 locations 2026-08-11
notable Trial sites expanded: 9 -> 26 locations 2026-06-24
critical Recruitment opened 2026-04-02
notable Trial sites expanded: 0 -> 8 locations 2026-04-02
Trial Details
NCT Number NCT07146906
Lead Sponsor Novartis Pharmaceuticals
Conditions Immunoglobulin A Nephropathy (IgAN)
Enrollment 32 participants
Start Date 2026-03-26
Primary Completion 2030-07-12 (estimated)
Study Completion 2030-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-10